Compare LFVN & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | NTRB |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 72.6M |
| IPO Year | 1996 | 2019 |
| Metric | LFVN | NTRB |
|---|---|---|
| Price | $6.24 | $7.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 46.4K | ★ 98.2K |
| Earning Date | 05-06-2026 | 05-29-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $203,204,000.00 | $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $2.80 |
| 52 Week High | $11.71 | $9.00 |
| Indicator | LFVN | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 62.29 |
| Support Level | $6.12 | $3.68 |
| Resistance Level | $6.78 | N/A |
| Average True Range (ATR) | 0.30 | 0.97 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 33.77 | 61.47 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.